Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients



Status:Recruiting
Conditions:Cancer, Cancer, Cancer, Obesity Weight Loss, Other Indications, Pancreatic Cancer
Therapuetic Areas:Endocrinology, Oncology, Other
Healthy:No
Age Range:18 - Any
Updated:6/2/2018
Start Date:April 27, 2015
End Date:April 2019
Contact:Sandra Lewis
Email:Sandra.Lewis@cshs.org
Phone:310-423-1047

Use our guide to learn which trials are right for you!

A Longitudinal, Single Institution Study Evaluating Weight Stability in Advanced Pancreatic Cancer Patients With Cachexia Who Are Receiving Enteral Feeding

Eligible patients will have a diagnosis of both pancreatic adenocarcinoma and cachexia
defined as greater than 5% unintentional weight loss within 6 months prior to screening
visit. Patients must be greater than 18 years of age; and have greater than 3 months life
expectancy.

This study will observe a standard of care intervention (tube feeding) for potential benefit.
Peptamen will be administered through a jejunal or a gastrojejunal feeding tube and dosing
will be calculated using the Mifflin St. Jeor equation. It will be administered daily for the
duration of the protocol.

In this study, we will prospectively evaluate advanced pancreatic adenocarcinoma patients
with cachexia, who are receiving enteral feeding, with a peptide based diet (medical food),
through a jejunal or gastrojejunal feeding tube. We plan to collect serum samples routinely
and establish a cohort of patients with this clinical syndrome. Our aims are to establish the
feasibility and efficacy of enteral nutrition and its relationship to meaningful clinical
outcomes. Furthermore, we will assess for a correlation between cachexia, activity, and
patient reported outcomes on domains of quality of life in an optional activity tracker
sub-study.

Inclusion Criteria:

- Advanced or locally advanced pancreatic cancer patients (can include new or recurrent
diagnosis) referred to SOCCI-CSMC for chemotherapy

- Cachexia defined as greater than 5% unexplained weight loss within 6 months prior to
screening visit or consultation with medical oncologist

- Candidate for enteral feeding with Peptamen, a peptide based formula. Must have
jejunal or gastrojejunal tube either previously placed or at least prior to Day 1 of
study

- ECOG performance status 0-2

- Greater than or equal to 3 month life expectancy

- Ability to understand and the willingness to sign a written informed consent

- May have received prior anti-cancer treatment, complete or partial resection of
primary tumor

- Patients must be ambulatory and have access to a smart phone to participate in the
activity tracker sub-study

Exclusion Criteria:

- Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse events

- Malignant ascites requiring paracenteses

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Bowel obstruction, partial or total

- Pregnancy
We found this trial at
1
site
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials